1Haidari M, Javadi E, Sadeghi B, et al. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem, 2001,33:309-315.
2Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes, 1995,44:369-374.
3Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly. Diabetes, 2001,50:2384-2388.
4Verma S, Li SH, Badiwada MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002,105:1890-1896.
5Dandona P, Aliada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and athelosclerosis. Am J Cardiol, 2002,90:27G-33G.
6Cabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med, 1999,340:448-454.
7Donald E. Increased levels of acute-phase serum proteins in diabetes. Metabolism, 1989,38:1042-1046.
8Pickup JC, Crook MA. Is type 2 diabetes mellitus a disease of the innate immune system. Diabetologia, 1998,41:1241-1248.
9Martin A, Crook P, John C, et al. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes. Diabetes Care, 2001,24:316-321.
10Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res, 1999,85:753-766.
